TORONTO, Feb. 22, 2012 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will report its fiscal 2012 first quarter financial results on Friday, March 9, 2012.
In conjunction with its financial results announcement, Patheon will host a conference call and Web cast on Friday, March 9, 2012 at 10:00 a.m. (EST). The financial results news release will be issued at approximately 7:30 a.m. (EST) on Friday, March 9, 2012.
Interested parties are invited to access the conference call, via telephone, toll free at 1-888-231-8191 (U.S., including Puerto Rico) and 1-647-427-7452 (Canada and International). To view the slides accompanying the conference call click here. The link to the Web cast will also be posted on the investor relations section of Patheon's Web site prior to the call. Participants are encouraged to dial in five to fifteen minutes in advance to avoid delays. A live audio will also be available via the web at http://ir.patheon.com/events.cfm. (Please note that either Windows Media Player or RealPlayer are required).
A telephone replay of the conference call will be available between Friday, March 9, 2012 and Friday, March 16, 2012 by dialling 1-855-859-2056 (toll free) or 1-403-451-9481, and by entering identification number 55107868, followed by the number key. The conference call will also be archived at http://ir.patheon.com/events.cfm.
Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. The company's integrated development and manufacturing network of 10 manufacturing facilities, nine development centers and one clinical trial material packaging facility across North America and Europe, enables customer products to be launched with confidence anywhere in the world.
For further information:
Investor Relations and Corporate Communications